Endeavour Capital Advisors’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-7,629
Closed -$4.19M 55
2022
Q1
$4.19M Sell
7,629
-4,639
-38% -$2.8M 0.67% 42
2021
Q4
$8.11M Sell
12,268
-5,214
-30% -$3.99M 1.14% 31
2021
Q3
$14.7M Buy
17,482
+2,463
+16% +$2.5M 2.12% 18
2021
Q2
$19.1M Buy
+15,019
New +$16.9M 2.43% 15

Other funds holding CDLX

Endeavour Capital Advisors's CDLX Position: Q2 2022 in Review

Endeavour Capital Advisors sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 7,629 shares — an estimated $4.19M sold.

Endeavour Capital Advisors first reported a position in CDLX in Q2 2021 and held it in 4 quarters. The position peaked at $19.1M in Q2 2021. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

  • Endeavour Capital Advisors reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
  • Endeavour Capital Advisors sold 7,629 Cardlytics shares in Q2 2022, an estimated $4.19M.
  • Endeavour Capital Advisors first reported a position in Cardlytics in Q2 2021 and held it in 4 quarters.
  • Endeavour Capital Advisors's Cardlytics position peaked at $19.1M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on Endeavour Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.